REGULATED PRESS RELEASE published on 05/23/2025 at 07:30, 1 year 5 months ago Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafonnée à 3 millions d’euros NFL Biosciences annonce une levée de fonds réussie de 3 millions d'euros pour financer son candidat médicament contre l'addiction au tabac. Allocation des fonds pour une étude de Phase 3 de NFL-101 NFL Biosciences NFL-101 Levée De Fonds Phase 3 Addiction Au Tabac
BRIEF published on 05/22/2025 at 17:50, 1 year 5 months ago NFL Biosciences Announces €2.2 Million Capital Increase NFL Biosciences Clinical Trials Capital Increase Biopharmaceuticals Investment Risks
BRIEF published on 05/22/2025 at 17:50, 1 year 5 months ago NFL Biosciences annonce une levée de fonds de 2,2 millions d'euros Augmentation De Capital NFL-101 Levée De Fonds Phase 3 Plateforme PrimaryBid
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 1 year 5 months ago NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voie d’augmentations de capital NFL Biosciences lance une levée de fonds de 2,2 millions d'euros pour étude sur le traitement des addictions avec nouveau médicament NFL-101 NFL Biosciences NFL-101 Levée De Fonds Addictions Étude Phase 3
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 1 year 5 months ago NFL Biosciences launches a capital increase of approximately €2.2 million NFL Biosciences launches a €2.2 million capital increase through global offering for smoking cessation drug development. Subscription price: €1.20/share NFL Biosciences Capital Increase Smoking Cessation Subscription Price Global Offering
BRIEF published on 05/21/2025 at 17:50, 1 year 5 months ago Résultats de l'Assemblée Générale de NFL Biosciences NFL Biosciences Actionnaires Assemblée Générale Biopharmaceutique Resolutions
BRIEF published on 05/21/2025 at 17:50, 1 year 5 months ago NFL Biosciences General Meeting Results NFL Biosciences Shareholders Biopharmaceuticals Resolutions General Assembly
REGULATED PRESS RELEASE published on 05/21/2025 at 17:45, 1 year 5 months ago NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025 Compte rendu de l'assemblée générale mixte de NFL Biosciences du 21 mai 2025. Résolutions approuvées pour le développement de médicaments botaniques innovants pour traiter les addictions NFL Biosciences Médicaments Botaniques Assemblée Générale Mixte Résolutions Approuvées Addictions
BRIEF published on 05/12/2025 at 08:35, 1 year 5 months ago NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement NFL Biosciences NFL-101 Phase 3 Trials Tobacco Addiction Scientific Committee
BRIEF published on 05/12/2025 at 08:35, 1 year 5 months ago NFL Biosciences renforce son Comité Scientifique pour le développement de NFL-101 NFL Biosciences NFL-101 Phase 3 Addiction Tabac Comité Scientifique
Published on 10/26/2026 at 13:30, 2 hours ago Stabilis Solutions Announces Third Quarter 2026 Conference Call and Webcast Date
Published on 10/26/2026 at 13:00, 2 hours 30 minutes ago BTU Commences Initial Drill Program on Hubcap Project Adjacent to RPX in Wawa
Published on 10/26/2026 at 15:18, 11 minutes ago EQS-Adhoc: Fraport AG Frankfurt Airport Services Worldwide: Preliminary Figures 3Q 2026
Published on 10/26/2026 at 14:43, 47 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 10/26/2026 at 14:36, 54 minutes ago Original-Research: Vossloh AG (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 10/26/2026 at 14:33, 57 minutes ago UPDATE ON STRATEGIC TRANSACTION, FURTHER PORTFOLIO DISPOSAL PROCESS AND CONTINUED LENDER SUPPORT
Published on 10/26/2026 at 14:28, 1 hour 1 minute ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 10/26/2026 at 11:27, 4 hours 3 minutes ago 261026 BENETEAU Transactions sur actions propres
Published on 10/26/2026 at 07:30, 8 hours ago EURAZEO’S SUPERVISORY BOARD APPOINTS CHRISTOPHE BAVIÈRE AS CHAIRMAN OF THE EXECUTIVE BOARD AND CEO
Published on 10/26/2026 at 07:30, 8 hours ago LE CONSEIL DE SURVEILLANCE D’EURAZEO NOMME M. CHRISTOPHE BAVIERE PRESIDENT DU DIRECTOIRE
Published on 10/23/2026 at 20:33, 2 days 18 hours ago Déclaration hebdomadaire d'opérations effectuées du 19 au 23 octobre 2026
Published on 10/23/2026 at 20:33, 2 days 18 hours ago Disclosure of transactions in own shares from October 19 to October 23, 2026
